Editorial: Community series in immunotherapy with checkpoint inhibitors for non-small cell lung cancer, colon cancer, and esophageal cancer, volume II

• Yueyi Li,
• Yusha Wang,
• Jinsheng Gao,
• Jinsheng Gao,
• Keqin Tan,
• Benjamin Frey,
• Udo S. Gaipl,
• Hubing Shi,
• Hubing Shi,
• Xuelei Ma

Affiliations

Yueyi Li

Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Yusha Wang

Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Jinsheng Gao

Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Jinsheng Gao

People’s Hospital of Yilong County, Nanchong, Sichuan, China

Keqin Tan

Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Benjamin Frey

Translational Radiobiology, Universitätsklinikum Erlangen, Erlangen, Germany

Udo S. Gaipl

Translational Radiobiology, Universitätsklinikum Erlangen, Erlangen, Germany

Hubing Shi

Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Hubing Shi

Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, China

Xuelei Ma

Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China